NRXP Share Price Performance
US$2.46
0.39 (18.84%)
Price US$2.46
Share PriceUS$2.46
NRXP Community Narratives
There are no narratives available yet.
Recent NRXP News & Updates
No updates
NRx Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.24
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- -33.4%
NRx Pharmaceuticals, Inc. Competitors
About NRXP
- Founded
- 2015
- Employees
- n/a
- CEO
- WebsiteView website
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
U.S. Market Performance
- 7 Days: 0.2%
- 3 Months: 12.2%
- 1 Year: 19.9%
- Year to Date: 7.6%
In the last week, the market has stayed flat, however the Consumer Staples sector stood out, gaining 3.2%. More promisingly, the market is up 20% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond.
Continue reading